Published on 21/12/2025
Expanded Access and Compassionate Use in the United Kingdom: Regulatory and Practical Insights
Expanded access and compassionate use programmes provide patients with serious or life-threatening conditions an opportunity to receive investigational medicines outside of standard clinical trials. In the United Kingdom (UK), these mechanisms play a vital role in balancing urgent patient needs with regulatory safeguards. The Medicines and Healthcare products Regulatory Agency (MHRA) has established frameworks such as the Early Access to Medicines Scheme (EAMS), alongside named patient supply routes and compassionate use protocols. These pathways ensure that patients who cannot enrol in trials still have potential access to promising therapies.
This article explores UK expanded access and compassionate use, focusing on regulatory structures, ethical oversight, NHS implementation challenges, and sponsor responsibilities.
Background and Regulatory Framework
MHRA’s Early Access to Medicines Scheme (EAMS)
Introduced in 2014, EAMS allows access to medicines that do not yet have marketing authorisation but demonstrate a positive benefit-risk profile in early trials. EAMS requires a scientific opinion from MHRA, and participation is voluntary for companies.
Named Patient Supply
UK law allows unlicensed medicines to be supplied to meet the special needs of an individual patient on the responsibility of a doctor.
HRA and Ethics Oversight
The Health Research Authority (HRA) and Research Ethics Committees (RECs) oversee compassionate use protocols, particularly when they resemble structured clinical programmes. Informed consent and patient safety remain central requirements.
Expanded Access and Compassionate Use: Key Insights
1. Patient Eligibility
Eligibility typically applies to patients with no satisfactory authorised therapies available and who cannot participate in clinical trials. Physicians must justify requests based on medical need.
2. Sponsor and Investigator Responsibilities
Sponsors must provide safety updates, maintain pharmacovigilance systems, and ensure traceability of investigational products. Investigators are responsible for monitoring patients and reporting adverse events.
3. Pharmacovigilance Obligations
Adverse events observed under compassionate use must be reported in line with clinical trial PV standards, ensuring data contribute to the overall safety profile of the drug.
4. NHS Implementation Challenges
Resource constraints and administrative burdens can delay access at NHS Trusts. Clear communication between treating physicians, sponsors, and NHS research offices is essential to streamline approvals.
5. Post-Brexit Divergence
Post-Brexit, UK compassionate use remains nationally governed, distinct from EU frameworks, though principles remain aligned with ethical and GCP standards.
Best Practices for Expanded Access in the UK
- Engage MHRA early for EAMS applications to clarify data expectations.
- Ensure CROs managing compassionate use programmes are trained in UK regulations.
- Document clear patient eligibility criteria and maintain transparency with RECs.
- Provide accessible patient information leaflets to aid informed consent.
- Integrate compassionate use safety data into ongoing development programmes.
Scientific and Regulatory Evidence
- Medicines for Human Use (Clinical Trials) Regulations 2004
- MHRA Early Access to Medicines Scheme (EAMS) Guidance
- HRA Guidance on Compassionate Use Protocols
- ICH E6(R2) – Good Clinical Practice
- UK Pharmacovigilance Requirements for Unlicensed Medicines
Special Considerations
- Oncology: Expanded access is often used for novel cancer drugs, with heavy demand from patient advocacy groups.
- Rare Diseases: Named patient supply is critical for ultra-rare conditions where formal trials may be unfeasible.
- Pediatrics: Special safeguards are required when children receive investigational medicines under compassionate use.
- Advanced Therapies (ATMPs): Gene and cell therapies may enter expanded access, requiring long-term follow-up obligations.
When Sponsors Should Seek Regulatory Advice
- When preparing EAMS applications for novel therapies.
- If planning multi-site compassionate programmes across NHS Trusts.
- For rare diseases with limited safety data available.
- When integrating compassionate use safety data into marketing submissions.
FAQs
1. What is the difference between EAMS and named patient supply?
EAMS provides a structured national pathway with MHRA scientific opinion, while named patient supply applies to individual cases based on physician judgement.
2. Are companies required to offer expanded access?
No. Participation is voluntary, but sponsors often engage to support patients and build safety datasets.
3. How does MHRA ensure safety in compassionate use?
Through pharmacovigilance reporting, scientific review in EAMS, and oversight of adverse event data.
4. What role does HRA play in compassionate programmes?
HRA reviews protocols that resemble trials to ensure ethical compliance, informed consent, and patient protection.
5. Can academic sponsors provide expanded access?
Yes, NHS Trusts and universities may support compassionate use, provided they comply with MHRA obligations.
6. Does Brexit change compassionate access rules?
UK schemes are independent post-Brexit but remain harmonised in principle with global frameworks.
7. Are costs covered under expanded access?
In some cases, sponsors provide products free of charge, but NHS reimbursement policies may vary.
Conclusion
Expanded access and compassionate use programmes in the UK provide vital treatment options for patients who cannot enrol in trials. With frameworks such as EAMS and named patient supply, MHRA and HRA ensure that patient safety and ethical standards are maintained. Sponsors, CROs, and NHS Trusts must work together to overcome administrative challenges, integrate safety data, and maintain transparency. These programmes not only provide immediate patient benefit but also strengthen the evidence base for regulatory decision-making.